UNSPSC 51171511: Algeldrate or aluminium hydroxide

This classification denotes a vaccine adjuvant with the molecular formula Al.3HO, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 5QB0T2IUN0, chemically known as aluminum hydroxide, dried (jp15/usp) but generally known as aluminium hydroxide, which bears US NIH Compound Identifier 6328211. European Medicines Agency schedules Aluminium hydroxide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB11700MIG.

World Health Organization schedules aluminium hydroxide in its Anatomical Therapeutic Chemical (ATC) Classification. Most nations schedule aluminium hydroxide under HS 28183000 and SITC 52266. SMILES: O.O.O.[AL].

UNSPSC 51171511 Algeldrate or aluminium hydroxide, a Commodity code, shows minimal alignment between its nominal scope and recent state and local procurement activity. The code's stated product—a specific pharmaceutical active ingredient—does not appear in the three recent opportunities posted under it. Instead, those opportunities span offender drug testing services, direct-to-manufacturer prescription programs, and generic pharmaceutical supply contracts that reference broad product categories rather than algeldrate specifically. The mismatch suggests either tagging error in the posting system or that the code captures a narrow ingredient rarely solicited at the state and local level in isolation.

Recent activity comes from Texas and Minnesota state agencies and a multistate cooperative purchasing vehicle. Collin County Community Supervision and Corrections Department posted an RFP on July 9, 2026 (due July 23, 2026) for offender specimen collection and drug testing services, valued at $600,000 over two years with three optional one-year renewals, requiring lab-certified vendors and comprehensive immunoassay and confirmatory testing. The Texas Health and Human Services Commission issued an RFI on April 3, 2026 to gather market intelligence on direct-to-manufacturer prescription programs, with no award value or formal timeline specified at that exploratory stage. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) opened an RFP on January 20, 2026 (due March 26, 2026) to establish multiple contracts for generic pharmaceuticals and OTC products distributed through AmerisourceBergen, Cardinal Health, and Morris & Dickson, with awards effective July 1, 2026. None of these opportunities specifically procure or reference algeldrate. The code appears to receive limited direct solicitation activity under its stated commodity definition at present.